NICE rejects Lilly’s Verzenios for advanced breast cancer
admin 15th February 2021 Uncategorised 0CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
More: NICE rejects Lilly’s Verzenios for advanced breast cancer
Source: News
